-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Differential diagnosis : T2 hyperintensity center scar
Differential diagnosis : T2 hyperintensity center scar diagnosis
Differential Diagnosis: T2 Bright Central Scar Differential Diagnosis: T2 Bright Central Scar
① T2 hyperintensity and higher signal central scar, peripheral nodular enhancement, continuous and progressive enhancement
① ① T2 hyperintensity and higher signal central scar, peripheral nodular enhancement, continuous and progressive enhancement-
T2 bright lesion
-
T2 brighter scar
-
Peripheral nodular enhancement
-
Persistent enhancement
T2 bright lesion
T2 bright lesion
T2 bright lesionT2 brighter scar
T2 brighter scar
T2 brighter scarPeripheral nodular enhancement
Peripheral nodular enhancement
Peripheral nodular enhancementPersistent enhancement
Persistent enhancement
Persistent enhancement
Huge and medium-sized blood vessels tumors
Huge and medium-sized blood vessels tumorshuge and medium-sized blood vessels of tumorblood vesselsGiant and a mid-size hemangioma
Giant and a mid-size hemangioma Giant and a mid-size hemangioma② T2 and other signals with slightly higher signal scars, obviously and evenly enhanced, cleared to equal signals
② ② T2 and other signals with slightly higher signal scars, obviously and evenly enhanced, cleared to equal signals-
T2 isointense
-
T2 slightly brighter scar
-
Homogeneous enhancement
-
fades to isointensity
T2 isointense
T2 isointense
T2 isointenseT2 slightly brighter scar
T2 slightly brighter scar
T2 slightly brighter scarHomogeneous enhancement
Homogeneous enhancement
Homogeneous enhancementfades to isointensity
fades to isointensity
fades to isointensity
Focal nodular hyperplasia (FNH)
Focal Nodular Hyperplasia (FNH) Focal Nodular Hyperplasia (FNH)Focal nodular hyperplasia
Focal nodular hyperplasia Focal nodular hyperplasia③ T2 mild hyperintensity and higher intensity scar, heterogeneous enhancement, clearance and capsule enhancement
③ ③ T2 mild hyperintensity and higher intensity scar, heterogeneous enhancement, clearance and capsule enhancement-
T2 slightly bright lesion
-
T2 brighter scar
-
Heterogeneous enhancement
-
Washout with capsular enhancement
T2 slightly bright lesion
T2 slightly bright lesion
T2 slightly bright lesionT2 brighter scar
T2 brighter scar
T2 brighter scarHeterogeneous enhancement
Heterogeneous enhancement
Heterogeneous enhancementWashout with capsular enhancement
Washout with capsular enhancement
Washout with capsular enhancement
Hepatocellular carcinoma (massive type)
Hepatocellular carcinoma (massive type)
Hepatocellular carcinoma Hepatocellular carcinoma
summary
Summary summary-
Evaluation on T2WI: the first case, hyperintensity lesion + higher intensity scar
-
Evaluation of the enhanced arterial phase: the first case, peripheral nodular enhancement
-
Assessment of enhanced portal phase: the first case, concentric progressive enhancement
-
Assess the enhancement delay period: the first case, continuous enhancement and no enhancement of the central scar
Evaluation on T2WI: the first case, hyperintensity lesion + higher intensity scar
Evaluation on T2WI: the first case, hyperintensity lesion + higher intensity scar
Evaluation on T2WI: the first case, hyperintensity lesion + higher intensity scar
Evaluation of the enhanced arterial phase: the first case, peripheral nodular enhancement
Evaluation of the enhanced arterial phase: the first case, peripheral nodular enhancement
Assessment of enhanced portal phase: the first case, concentric progressive enhancement
Assessment of enhanced portal phase: the first case, concentric progressive enhancement
Assess the enhancement delay period: the first case, continuous enhancement and no enhancement of the central scar
Assess the enhancement delay period: the first case, continuous enhancement and no enhancement of the central scar
.
In the second case, isosignal and central scar and separation enhancement
.
The third case was clarification and enhancement of false capsule
.
☆ Content source: English book "Liver MRI"
☆ Content source: English book "Liver MRI" ☆ Content source: English book "Liver MRI"Supplementary case and explanation
Supplementary case and explanationHepatocellular carcinoma , the main characteristics: enhanced scan "fast in and out", central fissure necrosis, obvious limited diffusion, false capsule
.
The main characteristics of hepatocellular carcinoma are: enhanced scan "fast in and out", central fissure necrosis, obvious limited diffusion, and false capsule
.
FNH , the main features: T2WI or other slightly higher signal, higher signal scar in the center, obvious tumor enhancement in the arterial phase, or slightly higher signal in the delayed phase, and iso-signal in the hepatobiliary phase
.
.
Liver metastases (liver puncture: small cell carcinoma; left lower lung occupancy was also found) , the main characteristics: small round shape, clear border, limited diffusion, lack of blood supply, delayed central enhancement
.
.
Liver lesions with central scars Liver lesions with central scars
Part of the data source: Differential diagnosis of imaging experts-Abdominal part booklet
Leave a message here